Bull & Bear

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — the entire debate converges on a single observable, and that observable does not print until November 2026. Bull and Bear agree on the facts; they disagree only on what those facts will become. The decisive tension is whether FY26's 1,200 bp operating-margin collapse to 4.89% is the absorption phase of a Unit II ramp (Bull) or the moment a sub-scale, governance-lite SME revealed it has no moat (Bear). Both cases name the same trigger — H1FY27 OPM in November 2026 — which means owning the stock today is paying for an answer you will not have for six months, in a name where the bear's governance and peer-margin evidence is hard to wave away. The evidence that would move this off Watchlist is either (a) the H1FY27 OPM print itself, or (b) a credible interim signal — FY26 annual report disclosure of bad-debt provisioning, a promoter buyback, or any reduction in DSO from 144.

Bull Case

Bull scenario: $0.62 per share over 18 months, conditional on FY25-level OPM (16.76%) returning by FY28. Method: 1.95x trailing book value ($0.33) on normalised earnings of $0.62–0.72M against ~$6.2M equity — below where Akums trades at 2.4x P/B and well below Caplin/Gland/JB Chem at 3.5–8.4x P/B. The window covers H1FY27 (Nov 2026) and FY27 full-year (May 2027). Triggering signal: H1FY27 OPM at or above 12%. Disconfirming signal: H1FY27 OPM below 7%, which would confirm FY26's collapse is structural rather than a ramp lag.

Bear Case

Bear downside scenario: $0.17 per share (–50% from $0.33 CMP, market cap $3.0M) over 12–18 months if FY26 proves structural. Method: FY26 book value $0.33/share, less ~$0.016/share write-down for likely bad-debt provisioning on $2.93M aged receivables at DSO 144, times 0.55x P/B reflecting FY26 ROCE of 1.14% that does not clear cost of debt — Akums trades at 2.4x P/B with 12% OPM and 14.9% ROCE, so halving profitability metrics justifies materially less than 1x book. Triggering signal: H1FY27 OPM at or below 7%, confirming Unit II's cost stack is the new normal. Cover signal: H1FY27 OPM at or above 12% AND DSO below 110 AND CFO positive for the half — all three together would mean the operating-leverage frame becomes investable rather than theoretical.

The Real Debate

Verdict

Watchlist. The Bear carries slightly more weight today because the OPM peer chart is the harder evidence — Onyx is the only listed Indian sterile CDMO whose margin broke the wrong way through FY22–FY26, and that pattern fits a sub-scale price-taker more cleanly than it fits a ramp-lag story. The single most important tension is whether the FY26 margin collapse was Unit II absorption or a no-moat reveal, and the Bull is not wrong to point at the H2FY26 430 bp half-on-half lift on flat revenue — that is genuine evidence of fixed-cost absorption, not a wish. The opposing side could still be right because the SME-listed disclosure regime (no quarterly results, no Ind-AS, audit committee seats the CFO) makes a structural bear thesis hard to falsify, and a tier-1 customer concentration with WHO-GMP segregation is not nothing in a Schedule M-consolidating industry. The durable thesis-breaker is whether FY25's 16.76% OPM was peak or normal; the near-term evidence marker that resolves it is the H1FY27 operating-margin print due November 2026 — at or above 12% moves this to Lean Long, at or below 7% moves it to Avoid. Until that print, position sizing is irrelevant because both sides agree the decisive variable is six months away from being observable.